Skip to main content

Table 1 Clinicopathologic characteristics of patient sample sets

From: The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

Characteristics Cohort 1
Training (total RNA-seq)
Cohort 2
Validation (NanoString)
RP cohort 3
Validation (NanoString)
Cohort 4
Liquid biopsies (NanoString)
RP cohort 1
LPC (n = 126)
MPC (n = 17) LPC (n = 35) MPC (n = 54) LPC (n = 191) LPC (n = 21) MPC (n = 6)
Sample type RP TURP RP (n = 22), TRUSbx (n = 13) TRUSbx RP Plasma/EVs Plasma/EVs
Median agea, years (IQR) 65.1 (59.2–68.7) NA 69.4 (62.8–73.0) 71.5 (67.9–74.1) 64.2 (61.5–67.6) 68.4 (64.9–72.8) 73.7 (67.7–74.8)
Median PSA at diagnosis (IQR) 10.8 (7.7–17.9) 46.0 (9.7–98.8) 9.2 (6.3–16.5) 30.0 (11.8–46.0) 10.2 (7.1–5.8) 9.1 (6.8–17.2) NA
Gleason Grade Groupb        
1 12 (9.5%) 1 (5.9%) 0 1 (1.9%) 61 (31.9 %) 1 (4.8%) 0
2 68 (54.0%) 1 (5.9%) 13 (37.1%) 1 (1.9%) 105 (55.0 %) 8 (38.1%) 0
3 22 (17.5%) 1 (5.9%) 9 (25.7%) 11 (20.4%) 0 5 (23.8%) 0
4 14 (11.1%) 5 (29.4%) 3 (8.6%) 23 (42.6%) 20 (10.5%) 4 (19.0%) 0
5 9 (7.1%) 8 (47.1%) 10 (28.6%) 17 (31.5%) 5 (2.6%) 2 (9.5%) 3 (50%)
Unknown 1 (0.8%) 1 (5.9%) 0 1 (1.9%) 0 1 (4.8%) 3 (50%)
T-stagec        
T1 0 0 8 (22.9%) 3 (5.6%) 0 4 (19.0%) 1 (16.7%)
T2 75 (59.5%) 2 (11.8%) 12 (34.3%) 15 (27.8) 140 (73.3 %) 13 (61.9%) 3 (50%)
T3 49 (38.9%) 2 (11.8%) 15 (42.9%) 33 (61.1%) 49 (25.7 %) 2 (9.5%) 2 (33.3%)
T4 1 (0.8%) 1 (5.9%) 0 2 (3.7%) 1 (0.3 %) 0 0
Unknown 1 (0.8%) 12 (70.6%) 0 1 (1.9%) 1 (0.5%) 2 (9.5%) 0
CAPRA-S risk nomogram        
Low risk 29 (23.0%) NA NA NA 47 (24.6%) NA NA
Intermediate risk 60 (47.6%) NA NA NA 100 (52.4%) NA NA
High risk 34 (27.0%) NA NA NA 36 (18.8%) NA NA
Unknown 3 (2.4%)     8 (4.2%)   
Surgical margin status        
Negative 82 (65.1%) NA NA NA 140 (73.3 %) NA NA
Positive 41 (32.5%) NA NA NA 51 (26.7 %) NA NA
Unknown 3 (2.4%)     0   
Recurrence status        
Recurrence-free 75 (59.5%) NA NA NA 108 (56.5 %) NA NA
Biochemical recurrence 50 (39.7%) NA NA NA 83 (43.5 %) NA NA
Unknown 1 (0.8%)     0   
Progression to MPC        
Progression free NA NA NA NA 180 NA NA
MPC progression NA NA NA NA 11 NA NA
Median follow-up time, months (IQR) 65.9 (45.3–102.6) NA 19.9 (14.2–22.7) NA 125.3 (98.8–141.7) NA NA
Survival status        
Alive 110 (87.3%) NA NA NA 155 (81.2%) NA NA
Dead 16 (12.7%) NA NA NA 36 (18.8%) NA NA
Non-malignant samples AN (n = 31, from LPC patients)   AN (n = 22, from 20 LPC and 2 MPC patients)   Control (n = 27, cancer-free at initial TRUSbx)
Median agea(IQR) 63.4 (58.1–66.5)   68.6 (61.7–71.8)   63.9 (58.5–68.3)
  1. Data is n (%) or median (IQR). aAge at time of sample collection. bFor cohort 4, biopsy Gleason Grade Group is stated. cFor RP cohorts 1 and 3, pathological T stage is stated and for all other samples, clinical T stage. IQR interquartile range, NA not available/not applicable